CRISPR Therapeutics AG (NASDAQ:CRSP) price on current trading day, rose 4.89% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $51.93.
A look at the stock’s price movement, the level at last check in today’s session was $49.51, moving within a range at $49.7506 and $52.3. The beta value (5-Year monthly) was 1.662. Turning to its 52-week performance, $91.10 and $43.42 were the 52-week high and 52-week low respectively. Overall, CRSP moved 2.39% over the past month.
CRISPR Therapeutics AG’s market cap currently stands at around $4.43 billion, with investors looking forward to this quarter’s earnings report slated for in January.
The average forecast suggests down to a -96.33% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 14.39M, representing a -96.12% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CRSP is a 50% Buy. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in Hold category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 6 recommend CRSP as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CRSP’s current price about 4.12% and 6.90% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 55.25, while 7-day volatility ratio is 5.28% and 5.00% in the 30-day chart. Further, CRISPR Therapeutics AG (CRSP) has a beta value of 1.63, and an average true range (ATR) of 2.50. Analysts have given the company’s stock an average 52-week price target of $75.5, forecast between a low of $59 and high of $100. Looking at the price targets, the low is -13.61% off recent price level in today’s trading while to achieve the yearly target high, it has to move -92.57%. Nonetheless, investors will most likely welcome a -45.39% jump to $75.5 which is the analysts’ median price.
If we refocus on CRISPR Therapeutics AG (NASDAQ:CRSP), historical trading data shows that trading volumes averaged 1.73 over the past 10 days and 1.40 million over the past 3 months. The company’s latest data on shares outstanding shows there are 85.34 million shares.
The 4.31% of CRISPR Therapeutics AG’s shares are in the hands of company insiders while institutional holders own 67.60% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 19.39 million on 2024-11-15, giving us a short ratio of 11.99. The data shows that as of 2024-11-15 short interest in CRISPR Therapeutics AG (CRSP) stood at 2575.0 of shares outstanding, with shares short rising to 17.59 million registered in 2024-10-15. Current price change has pushed the stock -17.04% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CRSP stock continues to rise going into the next quarter.
